

SUSTAINED-RELEASE MICROENCAPSULATED DELIVERY SYSTEM

Inventor: Eric H. Kuhrts

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to a process for manufacturing pharmaceutical formulations that results in sustained-release microparticles. These microparticles release a therapeutic agent gradually in a consistent fashion over a prolonged period of time, and can be manufactured in a way to yield a high percentage of drug core at a very economical cost. The process consists of heating and mixing a vegetable oil with a very high melting point with a therapeutic agent or drug until well coated, and then cooling to room temperature until hard. The resultant particles are small, free flowing, and exhibit release profiles that can be adjusted to extend from 6-24 hours. Other fibers, sugars, or polymers can be added in layers as an outer coat after cooling to effect the release profile and the hydrophobic properties of the particles, or directly to the matrix to accelerate drug release by creating additional channels for diffusion during erosion while dissolving. Other substances such as minerals can be added to the cores to provide additional weight to the particles causing them to sink due to heaviness.

The benefits of producing sustained-release formulations of drugs or other therapeutic agents is now widely recognized in the medical literature and is utilized in many commercial products. It is important to distinguish at the out-set between solid monolithic dosage forms such as tablets, and powders, and particles that are loosely packed into capsules. A sustained-release powder consists of microparticles that are microencapsulated using a manufacturing process that enables them to be ingested, as, for example a powdered drink-mix which can be added to a liquid and still retain its sustained-release and taste masking properties, or encapsulated in two piece hard shell gelatin capsules. Microencapsuled powders may behave differently when subjected to the high pressures required to form tablets, and may fracture in the process. In addition, sustained-release tablet formulations may employ other techniques that emanate from their large size,

surface area and the swelling properties of hydrocolloids. In this case, diffusion and solubility issues become important for sustained-release.

In the present invention, the drug particles are processed in a way to yield a high percentage of active component powder that is still small enough to be virtually indistinguishable from the original drug particles themselves. Surprisingly, drug cores consisting of 95% of the active agent are possible that release over a full 24-hour period.

In general, sustained-release dosage forms are multi-particle formulations that when ingested in capsule form, rapidly disintegrate into a large number of subunits. This is fine for drugs that are effective at relatively low doses, or dose levels that can fit into a capsule that is a reasonable size. The amount of drug that can fit into a two piece hard shell capsule that is easy for most people to swallow is at most about 800 mg. based on bulk density of the compound. But when large doses are required, such as for example with nutraceuticals, amino acids, or botanical substances, it is desirable to take them in a powder dosage form that can be mixed with a liquid and consumed.

There are many different ways to microencapsulate drugs producing sustained-release. Many of these methods can be found in "Microcapsules and Microencapsulation Techniques", 1976, M.H. Goucho, and Microcapsules and other Capsules, 1979, also by M.H. Goucho. Another resource book is "Aqueous Polymeric Coatings For Pharmaceutical Dosage Forms", 1989, Marcel Dekker, Inc. Most of the methods of producing sustained-release microparticles can be classified into either physical or chemical systems. Physical methods would include such techniques as pan coating, gravity-flow, centrifuge, and the Wurster Process. The Wurster Process employs a high velocity air stream that is directed through a cylindrical fluid bed in which the particles are suspended in the air. A coating is sprayed onto the suspended particles, and the particles flow out the top of the cylinder and descend back to the layer of fluid. The flow of air-dries the coating, so that successive layers can be applied repeatedly by further spraying. Variables that control the process include the number of cycles, temperature, pressure, and humidity, and can be used to provide the desired coating composition and thickness.

Chemical methods of microencapsulation are usually coacervation or phase separation. This technique involves dissolving the membrane forming polymer in a suitable solvent or vehicle and the drug to be dissolved is suspended in this solution and kept under agitation. The coating precipitates onto a droplet of the drug, similar to crystallization.

Fluid bed granulation or coating is one of the most common techniques used at the present time for small particle sustained-release. Fluidized bed equipment is available as "top spray", bottom spray", and "tangential-spray". The core drug is first preheated in the vessel to about 30°C with hot air, placing the particles in suspension. The floating particles are then sprayed with an aqueous suspension to provide a coating, while drying at the same time. Inlet temperature, spray rate, and air throughput must be adjusted to provide optimum end product. Furthermore, the finished particles must be subjected to a post-drying period at around 40°C, where any residual moisture can be driven off. In some case, this last drying period may be up to 24 hours.

Many of the polymers that are used to provide sustained-release properties to powders in the fluid bed process require solvents such as acetone, isopropyl alcohol, chlorinated solvents, alkanes, methyl ethyl ketone, cyclohexane, toluene, carbon tetrachloride, chloroform, and the like. Evaporation of the solvents becomes an environmental concern, and in many states, it is illegal to release these emissions into the atmosphere. Aqueous or water based polymers are limited mainly to ethyl cellulose and methacrylic acid esters such as poly methacrylate dispersions. In addition, 10-20% of a suitable plasticizer such as triethyl citrate must be added to the polymer. For example, U. S. patent # 5603957 uses a solvent-based polymer system to deliver aspirin over a 24-hour period. Preferred solvents are acetone/alkanol mixtures, or cyclohexane, toluene, or carbon tetrachloride. Castor oil, a low melting point oil, is also included in the polymer solvent mix.

Typical aqueous ethyl cellulose polymers currently in wide use include; Surelease®, Colorcon, West Point, PA, and Aquacoat®, FMC Corporation, Philadelphia, PA. In the Aquacoat® brochure available on their web site, it is recommended that for sustained-release applications, at least a two hour curing time at 60°C be conducted to insure reproducible release profiles. This should be done in a tray dryer. Subjecting drugs and other therapeutic compounds such as

botanical extracts to 60°C temperatures for 2 hours or more is likely to result in a loss of potency or degradation of active principles, and is especially problematic for substances with low melting points. Botanical extracts, in particular, have many volatile compounds that can be destroyed if kept at high temperatures for long periods.

Another polymer in common use for sustained-release applications is Eudragit®, Huls America, Somerset NJ. This is a neutral methacrylic acid ester with a small proportion of trimethylammonioethyl methacrylate chloride. This polymer is also applied using the fluid bed process, or can be used in a standard wet granulation procedure. Wet granulation involves mixing the drug or therapeutic agent with water in a conventional high-speed mixer until a pasty mass, and then dried in an oven over 24 hours at 60°C.

Wet granulations have the additional draw back in that they can effect the potency of botanical extracts by causing instability, or transformation. In addition, when dried at 60°C, many sensitive active principles are lost.

Carnauba wax has also been used to produce sustained-release dosage forms. Usually, at least a 15% level of wax is applied to the drug for the core, followed by a further coat of ethyl cellulose and polyvinylpyrrolidone (PVP) at about 10 to 15% by weight. This results in drug levels in the cores that range from 50 to 70 %, with the other 50 to 30% being the wax and polymers.

Synthetic waxes are also available such as Syncrowax®, available from Croda Inc., Parsippany, NJ. These triglyceride waxes have properties similar to carnauba wax, and have melting points of 60-75°C.

Another method of producing sustained-release particles is by starting with sugar spheres or nonpareils. The sugar spheres are also processed in a fluid bed granulator, but the drug must be dissolved in a aqueous solution and sprayed onto the sugar spheres, followed by spray coating with polymers that produce sustained-release as previously mentioned. This system results in large particles that are not acceptable in most drink mix applications, and botanical extracts cannot be dissolved enough to use in this system. The therapeutic agent needs to be absorbed

1964-1965
 1965-1966
 1966-1967
 1967-1968
 1968-1969
 1969-1970
 1970-1971
 1971-1972
 1972-1973
 1973-1974
 1974-1975
 1975-1976
 1976-1977
 1977-1978
 1978-1979
 1979-1980
 1980-1981
 1981-1982
 1982-1983
 1983-1984
 1984-1985
 1985-1986
 1986-1987
 1987-1988
 1988-1989
 1989-1990
 1990-1991
 1991-1992
 1992-1993
 1993-1994
 1994-1995
 1995-1996
 1996-1997
 1997-1998
 1998-1999
 1999-2000
 2000-2001
 2001-2002
 2002-2003
 2003-2004
 2004-2005
 2005-2006
 2006-2007
 2007-2008
 2008-2009
 2009-2010
 2010-2011
 2011-2012
 2012-2013
 2013-2014
 2014-2015
 2015-2016
 2016-2017
 2017-2018
 2018-2019
 2019-2020
 2020-2021
 2021-2022
 2022-2023
 2023-2024
 2024-2025
 2025-2026
 2026-2027
 2027-2028
 2028-2029
 2029-2030
 2030-2031
 2031-2032
 2032-2033
 2033-2034
 2034-2035
 2035-2036
 2036-2037
 2037-2038
 2038-2039
 2039-2040
 2040-2041
 2041-2042
 2042-2043
 2043-2044
 2044-2045
 2045-2046
 2046-2047
 2047-2048
 2048-2049
 2049-2050
 2050-2051
 2051-2052
 2052-2053
 2053-2054
 2054-2055
 2055-2056
 2056-2057
 2057-2058
 2058-2059
 2059-2060
 2060-2061
 2061-2062
 2062-2063
 2063-2064
 2064-2065
 2065-2066
 2066-2067
 2067-2068
 2068-2069
 2069-2070
 2070-2071
 2071-2072
 2072-2073
 2073-2074
 2074-2075
 2075-2076
 2076-2077
 2077-2078
 2078-2079
 2079-2080
 2080-2081
 2081-2082
 2082-2083
 2083-2084
 2084-2085
 2085-2086
 2086-2087
 2087-2088
 2088-2089
 2089-2090
 2090-2091
 2091-2092
 2092-2093
 2093-2094
 2094-2095
 2095-2096
 2096-2097
 2097-2098
 2098-2099
 2099-2100
 2100-2101
 2101-2102
 2102-2103
 2103-2104
 2104-2105
 2105-2106
 2106-2107
 2107-2108
 2108-2109
 2109-2110
 2110-2111
 2111-2112
 2112-2113
 2113-2114
 2114-2115
 2115-2116
 2116-2117
 2117-2118
 2118-2119
 2119-2120
 2120-2121
 2121-2122
 2122-2123
 2123-2124
 2124-2125
 2125-2126
 2126-2127
 2127-2128
 2128-2129
 2129-2130
 2130-2131
 2131-2132
 2132-2133
 2133-2134
 2134-2135
 2135-2136
 2136-2137
 2137-2138
 2138-2139
 2139-2140
 2140-2141
 2141-2142
 2142-2143
 2143-2144
 2144-2145
 2145-2146
 2146-2147
 2147-2148
 2148-2149
 2149-2150
 2150-2151
 2151-2152
 2152-2153
 2153-2154
 2154-2155
 2155-2156
 2156-2157
 2157-2158
 2158-2159
 2159-2160
 2160-2161
 2161-2162
 2162-2163
 2163-2164
 2164-2165
 2165-2166
 2166-2167
 2167-2168
 2168-2169
 2169-2170
 2170-2171
 2171-2172
 2172-2173
 2173-2174
 2174-2175
 2175-2176
 2176-2177
 2177-2178
 2178-2179
 2179-2180
 2180-2181
 2181-2182
 2182-2183
 2183-2184
 2184-2185
 2185-2186
 2186-2187
 2187-2188
 2188-2189
 2189-2190
 2190-2191
 2191-2192
 2192-2193
 2193-2194
 2194-2195
 2195-2196
 2196-2197
 2197-2198
 2198-2199
 2199-2200
 2200-2201
 2201-2202
 2202-2203
 2203-2204
 2204-2205
 2205-2206
 2206-2207
 2207-2208
 2208-2209
 2209-2210
 2210-2211
 2211-2212
 2212-2213
 2213-2214
 2214-2215
 2215-2216
 2216-2217
 2217-2218
 2218-2219
 2219-2220
 2220-2221
 2221-2222
 2222-2223
 2223-2224
 2224-2225
 2225-2226
 2226-2227
 2227-2228
 2228-2229
 2229-2230
 2230-2231
 2231-2232
 2232-2233
 2233-2234
 2234-2235
 2235-2236
 2236-2237
 2237-2238
 2238-2239
 2239-2240
 2240-2241
 2241-2242
 2242-2243
 2243-2244
 2244-2245
 2245-2246
 2246-2247
 2247-2248
 2248-2249
 2249-2250
 2250-2251
 2251-2252
 2252-2253
 2253-2254
 2254-2255
 2255-2256
 225

U.S. Patent No. 5700471 involves subjecting an aqueous dispersion of a drug or dye to turbulent mixing at a temperature that is above the melting point of the dye or drug, producing a melt emulsion which is then spray dried or converted into a suspension by cooling.

U.S. Patent No. 4855326 discloses combining sugar with low melting point oils such as vegetable oil, baby oil, margarine, cocoa butter and the like to help overcome hydrophobic properties and facilitate dispersion in water. None of the oils are solid at room temperatures or have high melting points. The oils themselves are not providing sustained-release properties.

In another process, ethyl cellulose, polyvidone and a small amount of castor oil are dissolved in acetone and isopropanol and sprayed onto aspirin particles in a fluid bed granulator such as is described in U.S. Patent No. 5603957. In this case the oil is liquid at room temperatures, and is being used as a plasticizer. The polymers are providing the sustained-release properties, not the oil. Castor oil itself cannot be used as a solid coating material because of its low melting point.

SUMMARY OF THE INVENTION

It is the object of the present invention to provide a sustained-release microencapsulation process that can be produced inexpensively and quickly and result in a very high percentage of active substance in the core. It is a further advantage of the instant invention not to necessitate the use of solvents or synthetic polymers, although polymers can be used as an additional means of control if desired. It is a further advantage of the present invention not to require extremely high temperatures to produce the microspheres, and to shorten the length of time the materials are processed or exposed to elevated temperatures.

In accordance with the invention, there is provided a microsphere that is produced by mixing the therapeutic agent with a hot vegetable oil with a melting point at least above 110°C, and preferably about 160 degrees F, in a vertical or horizontal high intensity shear mixer until the particles of the core substance are thoroughly mixed with the oil, and then cooling the hot melt to produce fine particles that exhibit excellent sustained-release properties. Surprisingly, the entire process can be completed in about 10 minutes or less, utilizing the work input of the mixer to melt the oil and intimately mix it with the core agent. The ideal high temperature melting point oil for this process is a hydrogenated soy oil with a maximum iodine value of 5.0 and a melting point of 150-160°C. Such an oil with these specifications is Dritex S® in flake form or Sterotex HM® which is a spray chilled powder. Both are available from AC Humko, Memphis TN. The melting point profile is more uniform if the spray chilled powder is used.

The apparatus that is used to manufacture the powder can be a Littleford vertical or horizontal high intensity mixer (Littleford, Florence KY), or a standard Hobart type mixer or plow mixer that is jacketed with a hot water bath. If the Littleford high intensity shear mixer is used, the oil or fat is melted by the work input from the mixer itself, which is a screw type auger shaft that resides within the vessel. The unique mixing action of the auger shaft revolving at a high rate of speed causes the particles to fluidize in free space, providing a high volume rate of material transfer throughout the entire length of the vessel. This results in the mixing, blending and melting of the oil with the other core materials all in the same process and within minutes. The vessel is also jacketed so it can be kept at the melting point temperature of the oil. In addition, the vessel can be fitted with high speed impact choppers to enhance mixing and or drying. After processing this way, the material is cooled and discharged as a free flowing powder.

If desired, the molten oil can be sprayed on from a heating tank fitted with heated insulated lines using a tower-mounted, hydraulic atomizing nozzle. If sprayed onto the core material, the work input is not needed to melt the oil because it is already melted, and less shear is needed. This results in less compaction of the particles because more shear results in harder particles. In some cases this may be desirable for shorter release profiles. Surprisingly, the high shear mixer with good compaction of the oil/core particles can result in sustained-release profiles that span over 24 hours with only a 3-5% by weight oil level. In other words, 95-97% of the powder is the core material. This sustained-release powder is of fine particle size and exhibits excellent flow properties, and may be used as a food additive, incorporated into a powdered drink mix, or manufactured into solid dosage forms.

DETAILED DESCRIPTION OF THE INVENTION

While oils have been used in various sustained-release formulations, they are usually not the primary material that is providing the barrier to gastric erosion, or the coating material to microencapsulate the substance. Most of the oils used are liquid or soft at room temperature.

Oils such as low melting point vegetable oil, castor oil, baby oil, margarine, cocoa butter, paraffin, and the like have also been used in the pharmaceutical industry for a variety of

Ins
D4

purposes, but not as sustained-release agents. For example, soft oils are often used for suppositories. These oils cannot be used to provide solid particles at room temperature. Various resins and shellac have also been used, but usually not for sustained-release. Carnauba wax is widely used in pharmaceutical dosage forms.

DOT 020 9550460

An oil such as a hydrogenated soy oil with an iodine value of at about 5, and a melting point above 120 degrees F, will be solid at room temperatures. In fact, such an oil or fat with a melting point above 145 degrees F will allow melting to occur only at temperatures that are significantly above those temperatures normally encountered by food or pharmaceutical products, even during shipment on hot days. Just such an oil is Sterotex HM®, manufactured by AC Humko, Memphis TN, a spray chilled hydrogenated soy oil that completely melts at about 160°F. This oil is completely solid at lower temperatures, and is available as a powder. Other oils of similar melting points are available, but are usually in a solid mass, and must be chiseled or chipped apart, and therefore are difficult to use and weigh out. Some oils are available in flake form such as Dritex S from the same company. Either product is preferable to the solid mass hydrogenated soy oils. Any oil with a melting point above about 110°F will work, but the most desirable would be those oils with melting points from 120-200°F, and ideally about 120-180°F. These melting points are usually below the melting point of most drugs or therapeutic compounds, and are achievable using the above described equipment.

Ins
D11

Natural oils such as soy oil or other vegetable oils are most preferred. These oils are very acceptable to health conscious consumers, and appear user friendly on the label. Stearic acid is an oil that is derived from either animal or vegetable sources and has a melting point of about 70°C. USP stearic acid is primarily a mixture of stearic and palmitic acids.

Ins
D12

The core material may be selected from any suitable drug, therapeutic or prophylactic agent, food or botanical substance, fertilizer, or animal feed, which can be incorporated in the hot melt without losing substantial activity for the chosen therapy. A broad range of materials are therefore useful. Representative non-limiting classes of drugs useful include those falling into the following therapeutic categories:

Ace-inhibitors; anti-anginal drugs; anti-arrhythmias; anti-asthmatics; anti-cholesterolemics; anti-convulsants; anti-depressants; anti-diarrhea preparations; anti-histamines; anti-hypertensive drugs; anti-infectives; anti-inflammatory agents; anti-lipid agents; anti-manics; anti-nauseants; anti-stroke agents; anti-thyroid preparations; anti-tumor drugs; anti-tussives; anti-uricemic drugs; anti-viral agents; acne drugs; alkaloids; amino acid preparations; anabolic drugs; analgesics; anesthetics; angiogenesis inhibitors; antacids; antiarthritics; antibiotics; anticoagulants; antiemetics; antiobesity drugs; antiparasitics; antipsychotics; antipyretics; antispasmodics; antithrombotic drugs; anxiolytic agents; appetite stimulants; appetite suppressants; beta blocking agents; botanical substances, bronchodilators; cardiovascular agents; cerebral dilators; chelating agents; cholecystokinin antagonists; chemotherapeutic agents; cognition activators; contraceptives; coronary dilators; cough suppressants; decongestants; deodorants; dermatological agents; diabetes agents; diuretics; emollients; enzymes; erythropoietic drugs; expectorants; fertility agents; fungicides; gastro-intestinal agents; growth regulators; hormone replacement agents; hyperglycemic agents; hypnotics; hypoglycemic agents; laxatives; migraine treatments; mineral supplements; mucolytics; narcotics; neuroleptics; neuromuscular drugs; NSAIDs; nutritional additives; peripheral vaso-dilators; polypeptides; prostaglandins; psychotropics; renin inhibitors; respiratory stimulants; steroids; stimulants; sympatholytics; thyroid preparations; tranquilizers; uterine relaxants; vaginal preparations; vaso- constrictors; vago-dilators; vertigo agents; vitamins; wound healing agents.

Non-limiting examples of specific therapeutic agents which may be useful in the present invention can be chosen from the list which follows. Mixtures of these agents and their salts used for appropriate therapies are also contemplated: acetaminophen; acetic acid-, acetylsalicylic acid and its buffered form; albuterol and its sulfate; alcohol; alkaline phosphatase; allantoin; aloe; aluminum acetate, carbonate, chlorohydrate, hydroxide- alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin; ansacrine; amsalog; anethole; ascorbic acid; aspartame; aspirin, atenolol; bacitracin; balsam peru; BCNU (carmustine) beclomethasone dipropionate; benzocaine; benzoic acid; benzophenones; benzoyl peroxide; bethanechol; biotin; bisacodyl; bomyl acetate; brompheniramine maleate; buspirone; caffeine; calamine; calcium, calcium carbonate, casinate and hydroxide; camphor; captopril; cascara sagrada; castor oil; cefaclor; cefadroxil; cephalixin;

cetylalcohol; cetylpyridinium chloride; chelated minerals; chloramphenicol; chlorcyclizine hydrochloride; chlorhexidine gluconate; chloroxylenol; chloropentostatin; chlorpheniramine maleate; cholestyramine resin; choline bitartrate; chondrogenic stimulating protein; cimetidine hydrochloride; cinnamedrine hydrochloride; citalopram; citric acid; cocoa butter; cod liver oil; codeine and codeine phosphate; clonidine and its hydrochloride salt, clorfibrate; cortisone acetate; ciprofloxacin HC I; cyanocobalamin; cyclizine hydrochloride; danthron; dextbrompheniramine maleate; dextromethorphan hydrobromide; diazepam; dibucaine; diclofenac sodium; digoxin; diltiazem; dimethicone; dioxybenzone; diphenhydramine citrate; diphenhydramine hydrochloride; docusate calcium, potassium and sodium; doxycycline hyclate; doxylamine succinate; efavirenz; enalapril; enoxacin; erythromycin; estropipate; ethinyl estradiol; ephedrine; epinephrine bitartrate; erythropoietin; eucalyptol; ferrous fumarate, gluconate and sulfate; folic acid; fosphenytoin; 5-fluorouracil (5-FU) fluoxetine HCl; furosemide; gabapentin; gentamicin; gemfibrozil; glipizide; glycerin; glyceryl stearate; griseofulvin; growth hormone; guaifenesin; hexylresorcinol; hydrochlorothiazide; hydrocodone bitartrate; hydrocortisone and its acetate; 8-hydroxyquinoline sulfate; ibuprofen; indomethacin; inositol; insulin; iodine; ipecac; iron; isoxicam; ketamine; koalin; lactic acid; lanolin; lecithin; leuprolide acetate; lidocaine and its hydrochloride salt; lisinopril; liotrix; lovastatin; luteinizing hormone; LHRH (luteinizing hormone releasing hormone); magnesium carbonate, hydroxide, salicylate, trisilicate; mefenamic acid; meclofenamic acid; meclofenamate sodium; medroxyprogesterone acetate; methenamine mandelate; menthol; meperidine hydrochloride; metaproterenol sulfate; methyl nicotinate; methyl salicylate; methylcellulose; methsuximide; metronidazole and its hydrochloride; metoprolol tartrate; miconazole nitrate; mineral oil; minoxidil; morphine; naproxen and its sodium salt; nifedipine; neomycin sulfate; niacin; niacinamide; nicotine; nicotinamide; nitroglycerin; nonoxonyl-9; norethindone and its acetate; nystatin; octoxynol; octoxynol 9; octyl dimethyl PABA, octyl methoxycinnamate; omega-3 polyunsaturated fatty acids; orphenazone; oxolinic acid; oxybenzone; oxtriphylline; para-aminobenzoic acid (PABA); padimate O; paramethadione; pentastatin; peppermint oil; pentaerythritol tetranitrate; pentobarbital sodium; pheniramine maleate; phenobarbital; phenol; phenolphthalein; phenylephrine hydrochloride; phenylpropanolamine and its hydrochloride salt; phenytoin; phenelzine sulfate; piroxicam; polymyxin B sulfate; potassium chloride and nitrate; prazepam; procainamide hydrochloride; procaterol; propoxyphene and its HCl salt;

INS
Do

propoxyphene napsylate; pramiracetin; pramoxine and its hydrochloride salt; propranolol HC I; pseudoephedrine hydrochloride and sulfate; pyridoxine; quinapril; quinidine gluconate and sulfate; quinestrol; ralitoline; ranitadine; resorcinol; riboflavin; salicylic acid; sesame oil; shark liver oil; simethicone; sodium bicarbonate, citrate and fluoride; sodium monofluorophosphate; sucralfate; sulfanethoxazole; sulfasalazine; sulfur; tacrine and its FIC I salt; theophylline; terfenidine; thioperidone; trimethrexate; triazolam; timolol maleate; tretinoin; tetracycline hydrochloride; tolmetin; tolnaftate; triclosan; triprolidine hydrochloride; undecylenic acid; vancomycin; verapamil HC I; vidaribine phosphate; vitamins A, B, C, D, B1, B2, B6, B12, E, K; witch hazel; xylometazoline hydrochloride; zinc; zinc sulfate; zinc undecylenate.

Useful dosage forms include without limitation oral forms such as tablets, capsules, beads, granules, aggregates, powders, gels, solids, semi-solids, and suspensions. Injectable forms, lotions, transdermal delivery systems including dermal patches, implantable forms or devices, aerosols or nasal mists, suppositories, salves and ointments are also useful.

001020 95556460
The inventive compositions have great versatility in their application. The compositions can be used for wound management such as by direct application to burns, abrasions, skin diseases or infections and the like. Other uses such as packing agents for nasal wounds or other open wounds are also contemplated.

In certain preferred embodiments, an amino acid like substance such as L-arginine, or L-carnitine, sports supplements such as creatine monohydrate, a vitamin such as niacin or vitamin C may be the core material. A therapeutic substance such as garlic powder, astaxanthin, or polygonum cuspidatum root extract would be examples of botanical substances. Also in this category would be tocotrienols or co-enzyme Q-10. An anti-histamine such as loratadine would be desirable in a 24 hour release profile. Blood pressure medication is also a preferred class of drugs. Fertilizers and fungicides would be non-drug applications for the process. Slow release of fertilizers and fungicides in the soil is especially desirable for nitrogen containing formulas. In a sustained-release microcapsule, the nitrogen fertilizer will tend not to leach out of the soil when wet.

A variety of additives can be incorporated into the inventive compositions for their intended functions. These additives are usually used in small amounts. In some cases, additives such as hydrocolloids are used as suspending agents, as for example in a powdered drink mix that is reconstituted in liquid.

Useful additives include, for example, gelatin, vegetable proteins such as sunflower protein, soybean proteins, cotton seed proteins, peanut proteins, rape seed proteins, blood proteins, egg proteins, acrylated proteins; water-soluble polysaccharides such as alginates, carrageenans, guar gum, agar-agar, gum arabic, and related gums (gum ghatti, gum karaya, gum tragacanth), pectin; water-soluble derivatives of cellulose: alkylcelluloses, hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as: cellulose acetate phthalate (CAP), carboxyalkyl celluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as carboxymethyl cellulose and their alkali metal salts; water-soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters, polyvinylacetates, polyvinylalcohols, polyvinylacetatephthalates (PVAP), polyvinylpyrrolidone (PVP), PVP/vinyl acetate copolymer, and polycrotonic acids; also suitable are phthalated gelatin, gelatin succinate, crosslinked gelatin, shellac, water-soluble chemical derivatives of starch, cationically modified acrylates and methacrylates possessing, for example, a tertiary or quaternary amino group, such as the diethylan-finoethyl group, which may be quaternized if desired; and other similar polymers.

Processing aids such as sucrose, polydextrose, maltodextrin, lactose, maltose, and the like may also be used. In some cases where accelerated release is desired, a sugar may be incorporated into the hot melt. Since the oil coating is hydrophobic, incorporating a hydrophilic sugar in the hot melt helps counteract the tendency of the particles to float. The sugar also helps to increase the rate of release of the core material by providing solubility to the matrix. Other substances such as calcium carbonate or other minerals can be added to provide weight to the particles and effect the release profile.

Examples of classes of additives include excipients, lubricants, hydrocolloid suspending agents, buffering agents, disintegrating agents, stabilizers, foaming agents, pigments, coloring agents, fillers, bulking agents, sweetening agents, flavoring agents, fragrances, release modifiers, ect.

Examples:

Example 1:

INS
DIP

Niacin (nicotinic acid) is added to a plow mixer, which was capable of operating at high temperatures because it was jacketed with a second layer to allow hot water to flow around the vessel. The unit was fitted with a tower-mounted, hydraulic atomizing nozzle with heated tanks and heated/insulated lines to enable hot oil to be applied at high temperatures. A high speed chopper operating at 10 hp was fitted at the discharge point. Hydrogenated soy oil flakes(Dritex S®, AC Humko, Memphis, TN) with a melting point of about 80°C or 140-160°F was sprayed on the powder as it was mixing in vessel. Efficient coating or microencapsulation of the powder was achieved in about 30 minutes when a temperature of about 155°F was reached and the hot oil thoroughly mixed with the powder. Cooling was achieved by discharging the batch into a cooler mounted directly below the mixer. The resulting granules were small, free flowing, and exhibited sustained-release properties when a dissolution test was conducted. The weight percent of the niacin in the finished product was 90%, and the hydrogenated soy oil was 10%.

Dissolution Test

Protocol: Basket method

Media: water

Paddle speed: 50 RPM

Time points/ % released: 1hr-28%, 2hr-38%, 3hr-44%, and 6 hours-45%

Example 2

The amino acid L-arginine free base, was charged to a Littleford W-10 high shear mixer with a hot water jacket to allow circulating hot water to keep the vessel hot . After mixing for 1 minute at 1000 RPM, spray chilled hydrogenated soy oil powder(Sterotex HM®, AC Humko, Memphis

TN) was added to the vessel. The work input was increased to 2000 RPM and then adjusted down to about 600 RPM for 5 minutes. The high shear of the mixer melted the oil and mixed with the core ingredients. Surprisingly, the work input of the mixer itself provided enough energy to melt the oil without the need of a heating tank and lines to spray the hot oil as in the previous example. The powder was discharged into a cooler mounted below the unit. The resulting particles were small, powder like, free flowing, and exhibited excellent sustained-release properties with a 24 hour release profile at only a 5% by weight of oil.

Dissolution test

95% L-arginine free base/5% hydrogenated soy oil

L-arginine base assay	100%	
Time Release Pattern	1 hour	20%
	2 hrs	23%
	4 hrs	30%
	6 hrs	35%
	8 hrs	40%
	16 hrs	70%
	24 hrs	100%

Example 3

Creatine monohydrate is charged to a Littleford high shear mixer with calcium carbonate (5% by weight) and sucrose (10% by weight) and mixed at 1000 RPM. Sterotex HM® hydrogenated soy oil is added at a 5% level and the speed of rotation is increased to 2000 RPM to melt the oil, and then decreased to maintain the power draw to within the allowable motor amperage.

Unexpectedly, after 3-5 minutes the oil is fully melted and mixed with the core materials, and upon inspection, the batch is fully granulated. The powder is discharged into the cooling unit and appears as a fine granular, free flowing sustained-release powder.

Dissolution Test

Formulation:

Creatine monohydrate	80%
Sucrose	10%
Calcium Carbonate	5%
Hydrogenated soy oil (Sterotex HM®)	5%

Time Release Pattern:

1 hour	46%
2 hrs	63%
4 hrs	78%
6 hrs	85%
10 hrs	100%

While the present invention is described above in connection with the preferred or illustrative embodiments, those embodiments are not intended to be exhaustive or limiting of the invention, but rather, the invention is intended to cover any alternatives, modifications or equivalents that may be included within its scope as defined by the appended claims.